Abstract
The mammalian target of rapamycin (mTOR) plays a critical role in the regulation of cell growth, proliferation, and metabolism by integrating growth factor stimulation and energy/nutrient input through a complex signaling network. The mTOR kinase is a part of two structurally and functionally distinct multiple protein complexes, mTORC1 and mTORC2. The mammalian target of rapamycin complex 1 (mTORC1) is rapamycin-sensitive and mediates temporal control of cell growth by regulating several cellular processes, such as translation, transcription, and nutrient transport while the mammalian target of rapamycin complex 2 (mTORC2) is insensitive to rapamycin and is involved in spatial control of cell growth via cytoskeleton regulation. Here we discuss the mechanism of mTOR regulation in tumor malignancy through a variety of signaling pathways and the potential of mTOR inhibitors for the treatment of cancer.
Keywords: AKT, cancer therapeutics, mTOR, PI3K
Current Cancer Drug Targets
Title:Targeting the mTOR Pathway in Tumor Malignancy
Volume: 13 Issue: 3
Author(s): Hengmiao Cheng, Marlena Walls, Sangita M. Baxi and Min-Jean Yin
Affiliation:
Keywords: AKT, cancer therapeutics, mTOR, PI3K
Abstract: The mammalian target of rapamycin (mTOR) plays a critical role in the regulation of cell growth, proliferation, and metabolism by integrating growth factor stimulation and energy/nutrient input through a complex signaling network. The mTOR kinase is a part of two structurally and functionally distinct multiple protein complexes, mTORC1 and mTORC2. The mammalian target of rapamycin complex 1 (mTORC1) is rapamycin-sensitive and mediates temporal control of cell growth by regulating several cellular processes, such as translation, transcription, and nutrient transport while the mammalian target of rapamycin complex 2 (mTORC2) is insensitive to rapamycin and is involved in spatial control of cell growth via cytoskeleton regulation. Here we discuss the mechanism of mTOR regulation in tumor malignancy through a variety of signaling pathways and the potential of mTOR inhibitors for the treatment of cancer.
Export Options
About this article
Cite this article as:
Cheng Hengmiao, Walls Marlena, M. Baxi Sangita and Yin Min-Jean, Targeting the mTOR Pathway in Tumor Malignancy, Current Cancer Drug Targets 2013; 13 (3) . https://dx.doi.org/10.2174/1568009611313030005
DOI https://dx.doi.org/10.2174/1568009611313030005 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bioinorganic Chemistry: The Study of the Fate of Platinum-Based Antitumour Drugs
Current Chemical Biology Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoietic Malignancies
Current Pharmaceutical Design Structural and Functional Organization of miRNAs
Current Pharmacogenomics Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk
Current Cancer Therapy Reviews A Review of Pharmacological Treatment Options for Lung Cancer: Emphasis on Novel Nanotherapeutics and Associated Toxicity
Current Drug Targets STAT5 and STAT5 Inhibitors in Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry Nucleoside Transporter Proteins
Current Vascular Pharmacology Low-Dose Methotrexate (LD-MTX) in Rheumatology Practice - A Most Widely Misunderstood Drug
Current Rheumatology Reviews Current Perspective of Natural Alkaloid Carbazole and its Derivatives as Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry Epigenetic Targets and their Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Herpes Simplex Virus Vectors for the Nervous System
Current Gene Therapy The Influence of Cox-2 and Bioactive Lipids on Hematological Cancers
Current Angiogenesis (Discontinued) The Functions of Histone Modification Enzymes in Cancer
Current Protein & Peptide Science Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy
Current Cancer Drug Targets Aberrant Regulation of Translation Initiation in Tumorigenesis
Current Molecular Medicine Animal Modeling of Cancer Pathology and Studying Tumor Response to Therapy
Current Drug Targets Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies
Current Medicinal Chemistry The Offer of Chemistry to Targeted Therapy in Cancer
Recent Patents on Biotechnology Prognostic Parameters in Myeloid Malignancies in a Historical Context – From Microscopy to Individualized Medicine
Current Drug Targets Modulating Co-Stimulation During Antigen Presentation to Enhance Cancer Immunotherapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)